Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids: A Randomized Clinical Trial

Overview

Journal JAMA Intern Med

Publisher American Medical Association

Specialty General Medicine

Date 2025 Feb 17

PMID 39960730

Authors

William C Becker

Karen H Seal

David B Nelson

Beth M DeRonne

Allyson M Kats

Benjamin J Morasco

Joseph W Frank

Una E Makris

Jacob T Painter

Kelli D Allen

Amanda S Mixon

Amy Bohnert

Thomas E Reznik

Hildi J Hagedorn

Patrick Hammett

Brian Borsari

Catherine Baxley

Erin E Krebs

Affiliations

Soon will be listed here.

Abstract

Importance: Guidelines recommend dose reduction or discontinuation of long-term opioid therapy when harm outweighs benefit, but strategies to help patients do so are limited.

Objective: To test optionally switching to buprenorphine as a strategy for improving pain and reducing opioids among patients prescribed high-dose, full agonist long-term opioid therapy.

Design, Setting, And Participants: In this pragmatic, multisite, 12-month randomized clinical trial with masked outcome assessment, patients treated at Veterans Affairs primary care clinics were recruited from October 2017 to March 2021, with follow-up completed June 2022. Eligible patients had moderate to severe chronic pain despite high-dose opioid therapy (≥70 mg/d for at least 3 months). Patients were randomized to having the option to switch to buprenorphine or not having the option to switch.

Interventions: The buprenorphine option was discussed with eligible patients as part of a larger trial of collaborative pain care interventions. Those who switched had structured follow-up to optimize dosing and address adverse effects.

Main Outcomes And Measures: The primary outcome was Brief Pain Inventory total score at 12 months. The main secondary outcome was opioid dose in morphine milligram equivalents at 12 months.

Results: Of 207 included participants, 185 (89.4%) were male, and the mean (SD) age was 60.9 (10.2) years. A total of 104 were randomized to the buprenorphine option and 103 to the no buprenorphine option. In the buprenorphine option arm, 27 participants (26.0%) switched. Over 12 months, the mean (SD) Brief Pain Inventory score improved from 6.8 (1.5) to 6.1 (1.9; adjusted mean difference [AMD], -0.59; 95% CI, -0.89 to -0.29) in the buprenorphine option arm and from 6.8 (1.6) to 6.3 (1.7; AMD, -0.50; 95% CI, -0.81 to 0.20) in the no option arm (between-group AMD, -0.09; 95% CI, -0.52 to 0.34). Over 12 months, mean (SD) opioid dosage decreased from 157 (75) mg/d to 94 (98) mg/d in the buprenorphine option arm (AMD, -61.0 mg/d; 95% CI, -74.1 to -47.9) and from 165 (88) mg/d to 107 (89) mg/d (AMD, -58.5 mg/d; 95% CI, -71.6 to -45.4) in the no option arm (between-group AMD, -2.5 mg/d; 95% CI, -21.1 to 16.0).

Conclusions And Relevance: In this trial, outcomes did not differ between groups; both had small improvements in pain and substantial reductions in opioid dosage, but the proportion of participants who switched to buprenorphine was low.

Trial Registration: ClinicalTrials.gov Identifier: NCT03026790.

References

Krebs E, Jensen A, Nugent S, DeRonne B, Rutks I, Leverty D . Design, recruitment outcomes, and sample characteristics of the Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) trial. Contemp Clin Trials. 2017; 62:130-139. DOI: 10.1016/j.cct.2017.09.003. View

Becker W, Frank J, Edens E . Switching From High-Dose, Long-Term Opioids to Buprenorphine: A Case Series. Ann Intern Med. 2020; 173(1):70-71. DOI: 10.7326/L19-0725. View

Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi Jr J . Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014; 15(12):2087-94. DOI: 10.1111/pme.12520. View

Stein B, Sherry T, ONeill B, Taylor E, Sorbero M . Rapid Discontinuation of Chronic, High-Dose Opioid Treatment for Pain: Prevalence and Associated Factors. J Gen Intern Med. 2021; 37(7):1603-1609. PMC: 9130349. DOI: 10.1007/s11606-021-07119-3. View

Kosinski M, Bayliss M, Bjorner J, Ware Jr J, Garber W, Batenhorst A . A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003; 12(8):963-74. DOI: 10.1023/a:1026119331193. View

Volkow N, Frieden T, Hyde P, Cha S . Medication-assisted therapies--tackling the opioid-overdose epidemic. N Engl J Med. 2014; 370(22):2063-6. DOI: 10.1056/NEJMp1402780. View

Ballantyne J, Mao J . Opioid therapy for chronic pain. N Engl J Med. 2003; 349(20):1943-53. DOI: 10.1056/NEJMra025411. View

Inturrisi C . Clinical pharmacology of opioids for pain. Clin J Pain. 2002; 18(4 Suppl):S3-13. DOI: 10.1097/00002508-200207001-00002. View

Kean J, Monahan P, Kroenke K, Wu J, Yu Z, Stump T . Comparative Responsiveness of the PROMIS Pain Interference Short Forms, Brief Pain Inventory, PEG, and SF-36 Bodily Pain Subscale. Med Care. 2016; 54(4):414-21. PMC: 4792763. DOI: 10.1097/MLR.0000000000000497. View

10.

Berland D, Malinoff H, Weiner M, Przybylski R . When opioids fail in chronic pain management: the role for buprenorphine and hospitalization. Am J Ther. 2013; 20(4):316-21. DOI: 10.1097/MJT.0b013e31827ab599. View

11.

Walsh S, Preston K, Stitzer M, Cone E, Bigelow G . Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994; 55(5):569-80. DOI: 10.1038/clpt.1994.71. View

12.

Kahan B, Tsui M, Jairath V, Scott A, Altman D, Beller E . Reporting of randomized factorial trials was frequently inadequate. J Clin Epidemiol. 2019; 117:52-59. DOI: 10.1016/j.jclinepi.2019.09.018. View

13.

Moss L, Algera M, Dobbins R, Gray F, Strafford S, Heath A . Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. PLoS One. 2022; 17(1):e0256752. PMC: 8794186. DOI: 10.1371/journal.pone.0256752. View

14.

Krebs E, Becker W, Nelson D, DeRonne B, Jensen A, Kats A . Care Models to Improve Pain and Reduce Opioids Among Patients Prescribed Long-Term Opioid Therapy: The VOICE Randomized Clinical Trial. JAMA Intern Med. 2024; 185(2):208-220. PMC: 11791716. DOI: 10.1001/jamainternmed.2024.6683. View

15.

Powell V, Rosenberg J, Yaganti A, Garpestad C, Lagisetty P, Shannon C . Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review. JAMA Netw Open. 2021; 4(9):e2124152. PMC: 8427372. DOI: 10.1001/jamanetworkopen.2021.24152. View

16.

Henry S, Paterniti D, Feng B, Iosif A, Kravitz R, Weinberg G . Patients' Experience With Opioid Tapering: A Conceptual Model With Recommendations for Clinicians. J Pain. 2018; 20(2):181-191. PMC: 6349552. DOI: 10.1016/j.jpain.2018.09.001. View

17.

Weingart S, Gandhi T, Seger A, Seger D, Borus J, Burdick E . Patient-reported medication symptoms in primary care. Arch Intern Med. 2005; 165(2):234-40. DOI: 10.1001/archinte.165.2.234. View

18.

Matthias M, Henry S . Reducing Frustration and Improving Management of Chronic Pain in Primary Care: Is Shared Decision-making Sufficient?. J Gen Intern Med. 2021; 37(1):227-228. PMC: 8739407. DOI: 10.1007/s11606-021-06967-3. View

19.

Daitch J, Frey M, Silver D, Mitnick C, Daitch D, Pergolizzi Jr J . Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012; 15(3 Suppl):ES59-66. View

20.

Oldfield B, Edens E, Agnoli A, Bone C, Cervone D, Edmond S . Multimodal Treatment Options, Including Rotating to Buprenorphine, Within a Multidisciplinary Pain Clinic for Patients on Risky Opioid Regimens: A Quality Improvement Study. Pain Med. 2018; 19(suppl_1):S38-S45. DOI: 10.1093/pm/pny086. View